– UK, Cambridge – Feedback plc (AIM: FDBK), the specialist medical imaging technology company, announces that it has appointed David Crabb as Chief Executive Officer and a director of Feedback with immediate effect. This appointment will underpin the execution of the Company’s growth strategy following the first CE marked release of TexRAD; the Company’s patented quantitative image texture analysis technology for diagnostic radiological scans.

Mr Crabb brings 20 years of experience as an effective business leader to Feedback. Most recently he was Chief Executive Officer of Cambridge Online Systems, a major software company providing services to UK and international customers, which was acquired by the global IT group Columbus in December 2016. Under Mr Crabb’s management in 2011, Cambridge Online Systems delivered strong growth from a loss-making organisation to one with top-quartile financial results and was voted as one of the “Sunday Times Top 100 Companies to work for” in two consecutive years. Previously, Mr Crabb held director-level roles in medium-sized technology and outsourced solutions companies with revenues from £50 million to over £1 billion, responsible for business optimisation, sales and marketing and workforce leadership.

Dr Alastair Riddell, Chairman of Feedback plc, said: “Since the acquisition of Cambridge Computed Imaging Ltd and TexRAD Limited in 2014, Feedback plc has developed a strong reputation in the field of medical imaging and is privileged to be working with over 40 of the world’s leading research institutions. We recognise that a small, multi-disciplinary team has its limitations, which resulted in some operational delays over the past 12 months, so I am delighted that Feedback has attracted a highly experienced executive to complement the strong technical and regulatory expertise within the Company. Under David’s leadership, we are well-positioned to leverage our pioneering technology to create evidence-based imaging software, arming clinicians with innovative tools to improve patient outcomes.”

David Crabb, Chief Executive Officer of Feedback plc, commented: “I am impressed with the platform technologies and domain expertise at Feedback. The medical imaging and diagnostics market is a dynamic, fast-paced environment where disruptive technologies are very much needed. The opportunity is not without its challenges, as with all pioneering development, but as a small, ambitious company which has experienced both acquisition and organic growth, there is significant opportunity to optimise and expand Feedback’s operations. Our long-term vision is to lead global innovation in quantitative medical imaging analysis – I believe we have strong foundations to position ourselves at the forefront of this important field and I am looking forward to refining our strategy over the coming months.”

About Feedback plc

Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD, the Company’s patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world’s leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data.

For more information : http://www.fbk.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.